Previous 10 | Next 10 |
Gainers: Yumanity Therapeutics YMTX +46%. Babylon (BBLN) +11%. Sema4 (SMFR) +11%. Nano-X Imaging (NNOX) +10%. Satsuma Pharmaceuticals (STSA) +10%. Losers: Praxis Precision Medicines PRAX -63%. eFFECTOR Therapeutics (EFTR) -20%. Pear Therapeutics (PEAR) ...
Clinical-stage biotech Praxis Precision Medicines (NASDAQ:PRAX) announced plans to reduce its staff and operating expenses on Monday after its lead candidate, PRAX-114 failed as monotherapy in a Phase 2/3 trial for major depressive disorder (MDD). The company shares lost 69% in reac...
Clinical-stage biotech Praxis Precision Medicines (NASDAQ:PRAX) announced plans to reduce its staff and operating expenses on Monday after its lead candidate PRAX-114 failed as monotherapy in a Phase 2/3 trial for major depressive disorder (MDD). The trial was designed to evaluate PRAX-114 as...
Aria Study did not achieve statistical significance on the primary endpoint Strategic realignment to focus resources on Movement Disorders and Epilepsy franchises extends cash runway into 2024 BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. ...
Gainers: Zoom Video Communications (ZM) +7%. Praxis Precision Medicines (PRAX) +5%. VNET Group (VNET) +4%. ACV Auctions (ACVA) +4%. Lixiang Education Holding Co (LXEH) +3%. Losers: Meta Platforms (FB) -8%. The Trade Desk (TTD) -7%. Magnite (MGNI) -6%. Nkarta (NKTX) -5%. Roku (ROKU) ...
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition...
Gainers: Data Storage Corporation (DTST) +40%. Indonesia Energy Corporation (INDO) +30%. Harpoon Therapeutics (HARP) +28%. Pulse Biosciences (PLSE) +24%. Praxis Precision Medicines (PRAX) +24%. Xeris Biopharma Holdings (XERS) +24%. Griffon Corporation (GFF) +22%. New Concept Energy (GBR) +20%...
The following slide deck was published by Praxis Precision Medicines, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Praxis Precision Medicines, Inc. 2022 Q1 - Results - Earnings Call Presentation
Praxis Precision Medicines, Inc. (PRAX) Q1 2022 Earnings Conference Call May 9, 2022, 4:30 PM ET Company Participants Marcio Souza – President and Chief executive Officer Bernard Ravina – Chief Medical Officer Alex Kane – Vice President Investor Relations and Corporate Co...
Praxis Precision Medicines press release (NASDAQ:PRAX): Q1 GAAP EPS of -$1.51 misses by $0.21. As of March 31, 2022, Praxis had $222.5 million in cash, cash equivalents and marketable securities, compared to $275.9 million in cash, cash equivalents and marketable securities as of December 31,...
News, Short Squeeze, Breakout and More Instantly...
Praxis Precision Medicines Inc. Company Name:
PRAX Stock Symbol:
NASDAQ Market:
Praxis Precision Medicines Inc. Website:
2024-07-26 13:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 13:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-20 14:30:05 ET Piper Sandler analyst issues OVERWEIGHT recommendation for PRAX on May 20, 2024 12:01PM ET. The previous analyst recommendation was Overweight. PRAX was trading at $44.93 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...